Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

NCT03267186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic Cell Transplantation Recipient

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis

Sponsor

Andrew Rezvani

Collaborators

[object Object]
[object Object]